Ignite Creation Date:
2025-12-24 @ 11:49 PM
Ignite Modification Date:
2025-12-25 @ 9:43 PM
Study NCT ID:
NCT03957551
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-21
First Post:
2019-05-17
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma
Sponsor:
John Rieth
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-08-27
Start Date Type:
ACTUAL
Primary Completion Date:
2024-06-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2019-05-17
First Submit QC Date:
None
Study First Post Date:
2019-05-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-06-11
Results First Submit QC Date:
None
Results First Post Date:
2025-08-24
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-07
Last Update Post Date:
2025-10-21
Last Update Post Date Type:
ESTIMATED